ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO257

Anti-Diabetic Medication Use and Kidney Function in US Adults

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Murphy, Daniel P., University of Minnesota, Minneapolis, Minnesota, United States
  • Foley, Robert N., University of Minnesota, Minneapolis, Minnesota, United States
Background

The concordance of diabetes mellitus (DM) and chronic kidney disease (CKD) constitutes a major public health problem. Though notable therapeutic advances have occurred in the last decade, diabetes medication patterns in the U.S. DM-CKD population remain poorly delineated, particularly associations with declining kidney function. Hence, we examined anti-diabetic medication (ADM) use among adult National Health and Nutrition Examination Survey participants (2001 to 2016) with self-reported diabetes or HbA1c ≥ 7.0%.

Methods

Comparisons were based on two thresholds of creatinine-based estimated glomerular filtration rate (eGFR, 60 and 45 ml/min/1.73m2) and one threshold of urinary albumin to creatinine ratio (ACR, 30 mg/g).

Results

Renal function in US adults with DM was distributed as follows: eGFR ≥ 60 and ACR < 30 (≥ 60/<30)~60.1%, ≥ 60/≥30~20.1%, 45-59/<30~7.4%,45-59/≥30~3.9%, <45/<30~3.1% and <45/≥30~5.4%. Use of ≥ 1 ADM was more prevalent with CKD than without kidney dysfunction (79.5% vs. 75.3%, P=0.004). Following these same eGFR and ACR categories, use of ≥ 1 ADM was associated with worsening kidney function category (75.3%, 75.4%, 82%, 84.5%,80.9%, and 86.7%, P < 0.001), as were sulphonylurea (26.3%, 33.3%, 29.5%, 29.9%, 36.7%, and 36.5%, P=0.002), insulin (23.3%, 27.3%, 30.9%, 41.0%, 40.6%, and 54.3%, P < 0.001) and amylin analog (0%, 0.6%, 0%, 0%, 0%, and 1.2%, P=0.03) use. Worsening kidney function category was associated with lower proportions of ≥ 2 ADM (35.6%, 41.5%, 34.0%, 38.9%, 26.4%, and 33.2%, P=0.032), biguanide (51.8%, 50.7%, 40.9%, 41.3%,16.4%, and 11.2%, P < 0.001) and SGLT-2 inhibitor (2.9%, 1.8%, 0.9%, 1.3%, 1%, and 0.1%, P=0.044) use. No association was present for thiazolidinedione, dipeptidyl peptidase-4 inhibitor, alpha-glucosidase inhibitor, GLP-1 receptor agonist and meglitinide use.

Conclusion

One in five in the U.S. DM-CKD population do not use anti-diabetic medications, and medication patterns vary substantially with kidney function.